Late last week, Eli Lilly and Company broke ground on a $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley. The site is one of 10 new U.S. manufacturing sites announced since 2020 and one of four dedicated to injectable medicines and devices. Part of the company’s $50 billion push to expand medicine production in the U.S., the Lehigh Valley site will add capacity for the next generation of obesity treatments, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist.
“Obesity is one of the biggest health challenges of our time, and the science to treat it is moving quickly,” said Lilly Chair and CEO David A. Ricks. “Retatrutide is one of several next-generation medicines we’re developing that could help millions more people living with obesity, type 2 diabetes, or both. This $3.5 billion investment means we’ll be able to make these medicines in Pennsylvania for people here at home and around the world.”
The Lehigh Valley site, located in Fogelsville, is scheduled to be operational by 2031. Lilly expects the new facility to create 850 high-wage jobs including engineers, scientists, operations personnel, and lab technicians, along with approximately 2,000 construction jobs, as it is built and brought online.
Lilly Grows Throughout The U.S.
Lilly has announced 10 U.S. sites since 2020:
- Five will produce active pharmaceutical ingredients (API):
- Richmond, VA; Huntsville, AL; Houston, TX; and two sites in Lebanon, IN – Lebanon API and Lilly Medicine Foundry, which will focus on new production methods, making medicines for clinical trials
- Four will make injectable medicines and manufacture devices:
- Research Triangle Park and Concord, NC; Kenosha, WI; and Lehigh Valley, PA
- One will make genetic medicines in Lebanon, IN; Lebanon Advanced Therapies
“Today marks another historic milestone in Pennsylvania’s thriving life sciences sector and reinforces my Administration’s commitment to advancing innovation, strengthening the economy, and creating good-paying jobs across the Commonwealth,” remarked Pennsylvania Governor Josh Shapiro. “We secured this historic, life-changing investment thanks to Pennsylvania’s world-class workforce, research institutions, infrastructure, and resources, and my Administration will continue working hard to ensure Pennsylvania remains a place where groundbreaking discoveries can translate into meaningful economic opportunities and results for patients and families.”
By pairing a highly skilled workforce with advanced technologies and specialized manufacturing, the Lehigh Valley site will help support a reliable supply of safe, high-quality medicines. It will use state-of-the-art technologies, including machine learning, AI, digitally integrated systems and advanced data analytics, to drive right-first-time execution, with digital automation embedded throughout the site to streamline operations.
“Before a dose of medicine leaves one of our sites, each production run goes through more than 5,000 documented steps and each unit is imaged and inspected more than 70 times to check for defects,” explained Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations. “These are just a few examples of the quality control we take to protect our patients. Lehigh Valley will build on that discipline with next-generation automation and digital systems, so we can do things right the first time and help patients count on their medicines for years to come, made in Pennsylvania.”
The facility will be built and operated to the highest standards for safety, quality and environmental stewardship. The site is targeting a Leadership in Energy and Environmental Design (LEED) Gold certification, demonstrating Lilly’s focus on sustainable performance as it expands advanced manufacturing in the U.S.


